NEUROCRINE BIOSCIENCES
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood... disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.
NEUROCRINE BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1992-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.neurocrine.com
Total Employee:
251+
Status:
Active
Contact:
(858) 617-7600
Email Addresses:
[email protected]
Total Funding:
10 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-08-30 | Diurnal Group | Diurnal Group acquired by Neurocrine Biosciences | 48.3 M GBP |
| 1998-03-03 | Northwest Neurologic | Northwest Neurologic acquired by Neurocrine Biosciences | N/A |
Investors List
Venrock
Venrock investment in Post-IPO Equity - Neurocrine Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-02 | Xenon Pharmaceuticals | Neurocrine Biosciences investment in Post-IPO Equity - Xenon Pharmaceuticals | 30 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-30 | Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer |
Official Site Inspections
http://www.neurocrine.com Semrush global rank: 1.61 M Semrush visits lastest month: 15.68 K
- Host name: 20.119.8.58
- IP address: 20.119.8.58
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neurocrine Biosciences"
Home | Neurocrine Bioscience
Our purpose is to relieve suffering for people with great needs, but few options. Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing …See details»
About Us | neurocrine.com - Neurocrine Bioscience
Neurocrine Biosciences is focused on unlocking new discoveries for rare and under-addressed neurological, neuroendocrine, and neuropsychiatric conditions.See details»
Leadership - Neurocrine Biosciences - Neurocrine Bioscience
Our leadership team inspires a shared vision of delivering life-changing treatments to people with serious, under-addressed disorders. William H. Rastetter, Ph.D. has served on the Board of …See details»
Neurocrine Biosciences - Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). See details»
Neurocrine Biosciences - Crunchbase Company Profile …
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases. Neurocrine Biosciences reported strong growth in INGREZZA sales for Q4 and the full …See details»
Population Health Management Resources | Neurocrine Biosciences
Our commitment to population health includes providing resources and helpful information to those involved in the care of individuals with tardive dyskinesia (TD), and Huntington’s disease …See details»
Working at Neurocrine Biosciences - Great Place To …
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing …See details»
Neurocrine Biosciences and Takeda Announce Collaboration to …
Jun 16, 2020 · SAN DIEGO and Osaka, Japan, June 16, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) …See details»
Meet Our People | neurocrine.com - Neurocrine Bioscience
Based in San Diego, we lean into our casual West Coast vibes. However, we take the work we do seriously and never forget the link between our science and the people who need our help. …See details»
News Releases - Neurocrine Biosciences
Sep 12, 2024 · Neurocrine Biosciences to Present New Phase 3 CAHtalystâ„¢ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary …See details»
Neurocrine Biosciences Launches WHAT THE C@H?! Educational …
Apr 24, 2024 · WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current …See details»
Neurocrine Biosciences and Me2/Orchestra, in Partnership with …
SAN DIEGO and BOSTON, Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization …See details»
Coming together for Ingrezza - PharmaLive
Dec 9, 2021 · The Neurocrine organization did the raw science, took it completely through the clinical and development process, and now it’s the first FDA-approved treatment for tardive …See details»
Neurocrine Biosciences and Sosei Heptares Announce …
Nov 22, 2021 · Neurocrine Biosciences plans to submit an Investigational New Drug (IND) application and initiate a placebo-controlled Phase 2 study with HTL-0016878 as a potential …See details»
2021 ANNU AL REPORT - neurocrine.com
Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline with multiple mid-to-late-stage programs focused on diseases and disorders …See details»
Unblinded: Kevin Gorman on Neurocrine's rise, fall and future
Jun 18, 2019 · Gorman joined Neurocrine in 1993 as head of business development, coming on staff after working on the biotech’s launch at a venture capital firm. When Neurocrine went …See details»
What is Neurocrine Biosciences? Company Culture, Mission, Values
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to …See details»
Diseases & Conditions | Neurocrine Biosciences
We have an FDA-approved treatment for tardive dyskinesia and Huntington’s disease chorea, as well as a robust pipeline including multiple compounds in mid-to-late phase clinical …See details»
Neurocrine Biosciences Is Pioneering Therapies for Neurological …
Mar 15, 2024 · On Sept. 12, Neurocrine Biosciences published highly positive results of a pivotal clinical trial evaluating the efficacy and safety profile of crinecerfont for the treatment of adult …See details»
Pipeline - Neurocrine Bioscience
Our pipeline programs in neurology consist of investigational therapies targeting movement disorders, pediatric epilepsies, and other neurological conditions with high unmet need that …See details»